To further expand the therapeutic scope of the peptide vaccine, Greiner in that same year evaluated a high dose of RHAMM-R3 peptide in patients with acute myeloid leukemia (AML), multiple myeloma and myelodysplastic syndrome, where 4 out of nine patients showed an increase in CD8+ T cells and 3 showed positive clinical response (74). This evidence concerns the gene HMMR and acute myeloid leukemia.